Effect of hingupippali churnam on painful menstruation.
Phase 3
- Conditions
- Health Condition 1: N944- Primary dysmenorrhea
- Registration Number
- CTRI/2021/08/036081
- Lead Sponsor
- Dr K Thilagavathi Ammal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Primary dysmenorrhea
Age between 15 to 45 years
Regular menstrual cycle (21 to 35 days)
Women with moderate and severe pain ( > 4 in VAS scale)
Exclusion Criteria
Secondary dysmenorrhea
Irregular menstrual cycle and excessive bleeding
Use of IUCD or OCP
Women with mild pain (4 and < 4 in VAS scale)
Systemic diseases (DM,HTN)
Those who require surgical procedure (Endometriosis,Adenomyosis,Uterine Fibroid,Endometrial polyp)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie hingupippali churnam's efficacy in primary dysmenorrhea (N944)?
How does hingupippali churnam compare to NSAIDs in managing primary dysmenorrhea pain intensity and duration?
Which biomarkers correlate with response to hingupippali churnam in N944 patients?
What are the safety profiles and adverse event management strategies for hingupippali churnam in Phase III trials?
Are there synergistic combinations of hingupippali churnam with hormonal therapies for primary dysmenorrhea?